Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Insights, Forecast to 2025

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.
The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at 1205 million US$ in 2018 and will reach 8777.6 million US$ by the end of 2025, growing at a CAGR of 32.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on company, product type, end user and key regions.

This report studies the global market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor in these regions.
This research report categorizes the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market by top players/brands, region, type and end user. This report also studies the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer

PARP (Poly ADP-Ribose Polymerase) Inhibitor market size by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
PARP (Poly ADP-Ribose Polymerase) Inhibitor market size by Applications
Ovarian Cancer
Breast Cancer
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
Turkey
GCC Countries
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global PARP (Poly ADP-Ribose Polymerase) Inhibitor companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of PARP (Poly ADP-Ribose Polymerase) Inhibitor submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.